모티리움엠정(말레인산 돔페리돈 12.72 mg)에 대한 디엠정의 생물학적동등성 평가
Bioequivalence Assessment of DM Tablet to Motilium-M® Tablet
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The aim of this study was to evaluate the bioequivalence of two domperidone preparations. Bioequivalence assessment was conducted on 34 healthy volunteers who received two tablets (Domperidone Maleate, 12.72 mg/tablet) in the fasting state, in a randomized balanced 2×2 cross-over study design. This whole study was performed according to the implementation guidelines of the Korea Food Drug Administration. After dosing of two tablets, blood samples were collected serially for a period of 36 hours. Plasma was analyzed for domperidone by using LC/MS/MS assay method. The analysis system was validated in specificity, accuracy, precision, and linearity. AUCt, (the area under the plasma concentration-time curve from the zero-time to 36 hr) was calculated through the trapezoidal rule. Cmax (maximum plasma drug concentration) and Tmax (time to reach Cmax) were compiled from the plasma domperidone concentrationtime data of each volunteer. No significant sequence effect was found for the bioavailability parameters indicating that the cross-over design was properly performed. The 90%-Confidence intervals of the AUCt ratio and the Cmax were from log 0.8007 to log 1.1240 and log 0.8645- log 1.2483, respectively. These values were within the acceptable bioequivalence intervals between 0.80 and 1.25. Therefore, this study demonstrated that two formulations have bioequivalence with respect to the rate and extent of absorption.
Abstract
The aim of this study was to evaluate the bioequivalence of two domperidone preparations. Bioequivalence assessment was conducted on 34 healthy volunteers who received two tablets (Domperidone Maleate, 12.72 mg/tablet) in the fasting state, in a randomized balanced 2×2 cross-over study design. This whole study was performed according to the implementation guidelines of the Korea Food Drug Administration. After dosing of two tablets, blood samples were collected serially for a period of 36 hours. Plasma was analyzed for domperidone by using LC/MS/MS assay method. The analysis system was validated in specificity, accuracy, precision, and linearity. AUCt, (the area under the plasma concentration-time curve from the zero-time to 36 hr) was calculated through the trapezoidal rule. Cmax (maximum plasma drug concentration) and Tmax (time to reach Cmax) were compiled from the plasma domperidone concentrationtime data of each volunteer. No significant sequence effect was found for the bioavailability parameters indicating that the cross-over design was properly performed. The 90%-Confidence intervals of the AUCt ratio and the Cmax were from log 0.8007 to log 1.1240 and log 0.8645- log 1.2483, respectively. These values were within the acceptable bioequivalence intervals between 0.80 and 1.25. Therefore, this study demonstrated that two formulations have bioequivalence with respect to the rate and extent of absorption.
참고문헌 (16)
- Brogden R, "Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic", Drugs, 24(5), pp.360~400 (1982)
- Laduron P, "Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity", Biochem pharmacol, 28, pp.2161~2165 (1979)
- Prakash A, "Domperidone. A review of its use in diabetic gastropathy", Drugs, 56(3), pp.429~445 (1998)
- Mitchelson F, "Pharmacological agents affecting emesis. A review (Part II)", Drugs, 43(4), pp.443~463 (1992)
- Heykants J, "On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration", Eur J Drug Metab Pharmacokinet, 6(1), pp.61~70 (1981)
- Meuldermans W, "On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man", Eur J Drug Metab Pharmacokinet, 6(1), pp.49~60 (1981)
- Heykants J, "On the pharmacokinetics of domperidone in animals and man. I. Plasma levels of domperidone in rats and dogs. Age related absorption and passage through the blood brain barrier in rats", Eur J Drug Metab Pharmacokinet, 6(1), pp.27~36 (1981)
- Michiels M, "On the pharmacokinetics of domperidone in animals and man II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat", Eur J Drug Metab Pharmacokinet, 6(1), pp.37~48 (1981)
- Huang Y, "Pharmacokinetics and dose proportionality of domperidone in healthy volunteers", J Clin Pharmacol, 26(8), pp.628~632 (1986)
- Michaud V, "An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies", J Chromatogr B Analyt Technol Biomed Life Sci, 852(1), pp.611~616 (2007)
- Sivakumar T, "Multicriteria decision making approach and experimental design as chemometric tools to optimize HPLC separation of domperidone and pantoprazole", J Pharm Biomed Anal, 43(5), pp.1842~1848 (2007)
- Ali M, "Stability indicating simultaneous determination of domperidone (DP), methylparaben (MP) and propylparaben by high performance liquid chromatography (HPLC)", J Pharm Biomed Anal, 41(2), pp.358~365 (2006)
- Kim S, "Bioequivalence Assessmant of Domperidone Maleate Tablets in Healthy Korean Volunteers", The Jourmal of Applied Pharmacolory, 11, pp.145~150 (2003)
- Wu M, "Determination of domperidone in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers", Acta Pharmacol Sin, 23(3), pp.285~288 (2002)
- Zavitsanos A, "Determination of domperidone in human serum and human breast milk by high-performance liquid chromatography-electrospray mass spectrometry", J Chromatogr B Biomed Sci Appl, 730(1), pp.9~24 (1999)
- "식품의약품안전청 고시 제 2005-31호 (2005. 6. 7): ‘Ÿ생물학적동등성시험기준’Ÿ", ~